Trump's 100% Drug Tariff Splits Pharma; Lilly Foundayo Approved

President Trump just signed an executive order imposing 100% tariffs on imported branded drugs — but the exemptions create a two-tier pharma economy overnight.

Meanwhile, Lilly's oral obesity pill lands an FDA approval and a tariff headwind in the same forty-eight hours, and twelve billion dollars in deals just rescued biotech's entire first quarter. A lot to unpack.

Welcome to The Pharma Closeout for Thursday, April 2nd, 2026. I'm Alex Mercer.

And I'm Maya Patel. Let's get into it.

Here's what actually happened today. President Trump signed an executive order imposing tariffs of up to 100% on patented pharmaceutical products and ingredients imported into the U.S. — justified under a Section 232 national security investigation. Large companies have 120 days before the tariffs bite. Smaller companies get 180. But the real architecture is in who doesn't pay.

That's the part worth dissecting. Companies that have already struck pricing deals with the administration under the Most Favored Nation framework walk away exempt. Everyone else faces a 100% duty. This isn't trade policy in any conventional sense — it's a compliance incentive with a tariff wrapper.

And the market read that distinction immediately. Drug manufacturers as a group fell 1.36% on the day, but the damage was uneven. AbbVie dropped 2.86%. Amgen lost 1.51%. Lilly was down close to 2%. But healthcare plans climbed over a percent, and the broader healthcare sector actually finished up half a percent. The market isn't pricing a sector-wide hit — it's sorting companies into buckets.

The 120-day window is the variable everyone should be modeling right now. That's not an implementation date. It's a negotiating deadline. STAT is reporting that smaller drugmakers are already in active discussions with the White House on pricing deals. The administration built an on-ramp — and they expect companies to take it.

There's a geopolitical layer too. The UK government finalized a pharmaceutical trade deal today, per Reuters, ensuring tariff-free access for UK-made medicines. That's a direct reprieve for AstraZeneca and GSK. So the two-tier system isn't just domestic. It's international — and it rewards countries that negotiate, not just companies.

I think the risk that hasn't been fully priced is downstream. A 100% tariff on active pharmaceutical ingredients doesn't just inflate the cost of a finished tablet. It threatens formulation timelines for any company sourcing APIs from outside the U.S. Think about the budget math: if you're a mid-cap with a single-source API supplier overseas, that 120-day clock isn't just a pricing negotiation — it's a manufacturing continuity problem. If this survives past the negotiation window, the supply chain implications dwarf the sticker-price conversation.

Which means this executive order does double duty. It pressures pricing in the short term and reshapes manufacturing investment decisions over the next two to three years. Companies that had been slow-walking domestic manufacturing commitments now have a very different incentive structure.

That tariff uncertainty sits on top of what's been the most active deal stretch in years. STAT dubbed March 31st "Takeover Tuesday" — and the numbers earn the name. Eli Lilly announced a $6.3 billion acquisition of Centessa Pharmaceuticals, primarily for a sleep disorder asset. Hours later, Biogen unveiled a $5.6 billion buyout of Apellis, targeting immunology and nephrology. Those two deals, according to STAT, pulled the XBI back from a first-quarter loss. And they capped what Endpoints tallied as a $25.5 billion, eight-day acquisition spree. Let's bring in Marcus Webb on the deal structures here — Marcus, both transactions use contingent value rights, and that's worth pausing on.

Appreciate the read, Marcus. Elsewhere — quick hits. Merck struck an R&D collaboration with antibody discovery startup Infinimmune, worth up to $838 million, focused on immune cell-directed antibodies across multiple targets. Ambrosia Biosciences closed a $100 million Series B to push its oral GLP-1 into early human testing — the oral GLP-1 space keeps attracting capital. And Blackstone raised a record $6.3 billion life sciences fund, almost 40% larger than its predecessor vehicle. Capital is available. The question going forward is whether targets can justify current valuations once the tariff picture forces companies to reprice their supply chain exposure.

On the regulatory side — the FDA approved Lilly's oral obesity pill Foundayo, orforglipron, and analysts are already projecting blockbuster trajectory. Fierce Pharma reported high early expectations for the launch. But here's the disconnect worth watching: Lilly's stock still dropped close to 2%, closing at $935.58, with the tariff order burying the approval signal. Analyst one-year targets sit around $1,209 — that's a 29% gap between where the stock is and where the Street thinks it belongs. And Novo Nordisk wasted no time claiming its own obesity pill is superior, though as Endpoints correctly noted, only a head-to-head trial can settle that argument.

How seriously should we take Novo's positioning?

Claiming superiority without head-to-head data is a messaging play, not an evidence play. Payers aren't going to differentiate formulary positioning based on cross-trial comparisons. They're going to wait for real-world adherence curves and discontinuation rates — the kind of data that takes twelve months to accumulate. Foundayo's launch is a commercial execution story now, not a clinical one.

Also worth noting on the regulatory front — two approvals that flew under the tariff radar. Vertex won expanded FDA labels for both Alyftrek and Trikafta, broadening eligibility to approximately 95% of the U.S. cystic fibrosis population, according to the company's announcement. And Regeneron's EYLEA HD — aflibercept — was approved for extended dosing intervals of up to five months in wet AMD and DME, based on 96-week data from two pivotal trials. Per Regeneron's release, it's the only injectable anti-VEGF with intervals that long. For retinal specialists managing treatment burden, five-month dosing changes the compliance conversation entirely.

On the data side, AstraZeneca posted positive Phase 3 results from EMERALD-3. Imfinzi combined with Imjudo, lenvatinib, and TACE delivered a statistically significant improvement in progression-free survival for embolization-eligible hepatocellular carcinoma. They have a third study — EMERALD-2 — testing Imfinzi with Avastin in adjuvant liver cancer, data expected second half of this year. If that reads out cleanly, AstraZeneca will have positioned itself across the HCC treatment continuum, and that redraws the competitive map in hepatology for every oncology franchise team watching this space.

And one miss to flag. Lipocine's oral brexanolone — LPCN 1154 — failed its Phase 3 primary endpoint in postpartum depression. Ninety patients in the full analysis set. Primary endpoint at hour 60 — not met.

They disclosed a post hoc subset of 54 patients with prior psychiatric history that showed nominally significant results. Post hoc, on 54 patients, with subgroup selection after the miss — that's hypothesis-generating at the most generous read. It doesn't give Lipocine a credible path to a regulatory filing, and the PPD space remains underserved.

Looking ahead — the 120-day tariff clock starts now. Every major pharma company without an existing pricing deal is recalculating its negotiating posture this week. That's the macro catalyst. On the commercial side, the early analyst models on Foundayo will shape Lilly's stock narrative through Q2, and the Lilly-Novo oral obesity framing is going to intensify with every data release.

STAT published its Q2 biotech scorecard yesterday — 23 stock-moving events this quarter, including readouts from Allogene in B-cell lymphoma and Cytokinetics. Layer tariff uncertainty on top of that catalyst calendar, and the spread between clinical winners and losers widens considerably. The companies with clean data in Q2 get rewarded more than usual. The ones that miss get punished harder.

That is your Pharma Closeout for Thursday, April 2nd. A 100% tariff threat splitting pharma into haves and have-nots. Foundayo entering a crowded obesity market. Twelve billion in deals saving biotech's quarter. AstraZeneca building a liver cancer franchise one EMERALD at a time. This industry does not slow down — and honestly, neither do we. If this briefing keeps you sharp, follow us on Spotify, Apple Podcasts, or wherever you listen, and drop us a rating. We are back tomorrow.

Go enjoy your Thursday evening. See you tomorrow. ### Episode Metadata **Title:** Trump's 100% Drug Tariff Splits Pharma; Lilly Foundayo Approved; $12B Deal Week Rescues Biotech | Apr 02, 2026 **Description:** Trump signs 100% tariff on imported branded drugs—exemptions create pharma haves and have-nots. Lilly's oral obesity pill Foundayo wins FDA approval as analysts project blockbuster launch. Lilly-Centessa ($6.3B) and Biogen-Apellis ($5.6B) deals cap a $25.5B acquisition spree. **Tags:** Trump pharma tariff, pharmaceutical tariffs, Eli Lilly, Foundayo, orforglipron, FDA approval, obesity drugs, GLP-1, Novo Nordisk, Centessa, Biogen, Apellis, CVR, AstraZeneca, EMERALD-3, liver cancer, Vertex, cystic fibrosis, Alyftrek, Trikafta, EYLEA HD, Regeneron, aflibercept, Lipocine, postpartum depression, Merck, Infinimmune, Blackstone, Ambrosia, pharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, M&A, drug pricing #